IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are associated with disease-initiating stem cells that are not eliminated by conventional therapies. Novel therapeutic targets against preleukemic stem cells need to be identified for potentially curative strategies. We conducted parallel transcriptional analysis of highly fractionated stem and progenitor populations in MDS, AML, and control samples and found interleukin 8 (IL8) to be consistently overexpressed in patient samples. The receptor for IL8, CXCR2, was also significantly increased in MDS CD34(+) cells from a large clinical cohort and was predictive of increased transfusion dependence. High CXCR2 expression was also an adverse prognostic factor in The Cancer Genome Atlas AML cohort, further pointing to the critical role of the IL8-CXCR2 axis in AML/MDS. Functionally, CXCR2 inhibition by knockdown and pharmacologic approaches led to a significant reduction in proliferation in several leukemic cell lines and primary MDS/AML samples via induction of G0/G1 cell cycle arrest. Importantly, inhibition of CXCR2 selectively inhibited immature hematopoietic stem cells from MDS/AML samples without an effect on healthy controls. CXCR2 knockdown also impaired leukemic growth in vivo. Together, these studies demonstrate that the IL8 receptor CXCR2 is an adverse prognostic factor in MDS/AML and is a potential therapeutic target against immature leukemic stem cell-enriched cell fractions in MDS and AML.

[1]  P. Campbell,et al.  Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes , 2015, Nature Communications.

[2]  A. Verma,et al.  Stem cell origin of myelodysplastic syndromes , 2014, Oncogene.

[3]  R. Majeti,et al.  Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis , 2014, Leukemia.

[4]  S. Linnarsson,et al.  Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. , 2014, Cancer cell.

[5]  H. Ramshaw,et al.  Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC , 2014, Leukemia.

[6]  Thomas J. Hudson,et al.  Corrigendum: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia , 2014, Nature.

[7]  Lincoln D. Stein,et al.  Identification of pre-leukemic hematopoietic stem cells in acute leukemia , 2014, Nature.

[8]  Claudia Fischbach,et al.  Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. , 2013, Cancer research.

[9]  Sheng Wei,et al.  Induction of myelodysplasia by myeloid-derived suppressor cells. , 2013, The Journal of clinical investigation.

[10]  D. Neuberg,et al.  Toll-like receptor alterations in myelodysplastic syndrome , 2013, Leukemia.

[11]  R. Clarke,et al.  Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells , 2013, Breast Cancer Research.

[12]  R. Chen,et al.  Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes , 2013, PloS one.

[13]  Lesley A. Mathews,et al.  Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. , 2013, Cancer cell.

[14]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[15]  Alex S. Arvanitakis,et al.  Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. , 2013, Blood.

[16]  I. Weissman,et al.  Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia , 2013, Leukemia.

[17]  B. Jena,et al.  CXCR2 macromolecular complex in pancreatic cancer: a potential therapeutic target in tumor growth. , 2013, Translational oncology.

[18]  Rakesh K. Singh,et al.  Targeting CXCR2 Enhances Chemotherapeutic Response, Inhibits Mammary Tumor Growth, Angiogenesis, and Lung Metastasis , 2013, Molecular Cancer Therapeutics.

[19]  I. Weissman,et al.  Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes , 2013, Proceedings of the National Academy of Sciences.

[20]  U. Steidl,et al.  Concise Review: Preleukemic Stem Cells: Molecular Biology and Clinical Implications of the Precursors to Leukemia Stem Cells , 2013, Stem cells translational medicine.

[21]  Dajin Li,et al.  SB225002 Promotes Mitotic Catastrophe in Chemo-Sensitive and -Resistant Ovarian Cancer Cells Independent of p53 Status In Vitro , 2013, PloS one.

[22]  John V Heymach,et al.  CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. , 2013, Cancer research.

[23]  G. Landberg,et al.  Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms , 2012, Clinical Cancer Research.

[24]  C. Steidl,et al.  Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. , 2012, Blood.

[25]  O. Sansom,et al.  Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. , 2012, The Journal of clinical investigation.

[26]  I. Weissman,et al.  Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia , 2012, Science Translational Medicine.

[27]  S. Ben-Neriah,et al.  Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. , 2012, Blood.

[28]  H. Lenz,et al.  Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis , 2012, British Journal of Cancer.

[29]  H. Lenz,et al.  The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models , 2012, Molecular Cancer Therapeutics.

[30]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[31]  M. Konopleva,et al.  Leukemia stem cells and microenvironment: biology and therapeutic targeting. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Kraneveld,et al.  Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[33]  M. Carroll,et al.  Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. , 2011, The Journal of clinical investigation.

[34]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[35]  M. Kawahara,et al.  Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. , 2009, Blood.

[36]  L. Hood,et al.  Dysregulated gene expression networks in human acute myelogenous leukemia stem cells , 2009, Proceedings of the National Academy of Sciences.

[37]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[38]  Monica L Guzman,et al.  Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. , 2008, Blood.

[39]  M. Carroll,et al.  An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. , 2007, Blood.

[40]  Xiaojie Li,et al.  Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). , 2007, Blood.

[41]  R. Verhaak,et al.  A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. , 2007, The Journal of clinical investigation.

[42]  G. V. van Dongen,et al.  The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. , 2005, Blood.

[43]  Christian Steidl,et al.  Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells , 2006, Nature Genetics.

[44]  C. Jordan.  Searching for leukemia stem cells--not yet the end of the road? , 2006, Cancer cell.

[45]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[46]  M. Le Bousse-Kerdilès,et al.  IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. , 2005, Blood.

[47]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[48]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[49]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[50]  A. Verma,et al.  Activation of the p38 Mitogen-activated Protein Kinase Mediates the Suppressive Effects of Type I Interferons and Transforming Growth Factor-β on Normal Hematopoiesis* , 2002, The Journal of Biological Chemistry.

[51]  D. Howard,et al.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.

[52]  S. Hermouet,et al.  Interleukin-8: an autocrine/paracrine growth factor for human hematopoietic progenitors acting in synergy with colony stimulating factor-1 to promote monocyte-macrophage growth and differentiation. , 1999, Experimental hematology.

[53]  H. Broxmeyer,et al.  Involvement of Interleukin (IL) 8 receptor in negative regulation of myeloid progenitor cells in vivo: evidence from mice lacking the murine IL-8 receptor homologue , 1996, The Journal of experimental medicine.

[54]  H. Broxmeyer,et al.  High Activity Suppression of Myeloid Progenitor Proliferation by Chimeric Mutants of Interleukin 8 and Platelet Factor 4 (*) , 1995, The Journal of Biological Chemistry.

[55]  M. Ratajczak,et al.  Chemokine regulation of human megakaryocytopoiesis. , 1995, Blood.

[56]  R. Willemze,et al.  Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. , 1995, Blood.

[57]  W. Wood,et al.  Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. , 1994, Science.

[58]  A. Cerami,et al.  Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. , 1993, Journal of immunology.

[59]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.